Even though the clinical behavior of mutated gliomas seems to be similar to wildtype tumors, screening for the BRAF V600E mutation is recommended for younger patients diagnosed with glioblastoma and in tumors with predominantly temporal lobe location, because mutation specific targeted treatment options exist [67] and encouraging case reports have been published. Here, BRAF is linked to central nervous system cancer.